Health
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
TOKYO & BASKING RIDGE, N.J., October 19, 2025--Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom im
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/f81708d02ddffad400ae7a809d902591"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bxdgQNqjM_cpIRlsLOqjXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f81708d02ddffad400ae7a809d902591","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Daiichi Sankyo and AstraZeneca’s DATROWAY also demonstrated a highly statistically significant and clinically meaningful 43% reduction in patients’ risk of disease progression or death","length":184,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this patient population","length":127,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":311,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., October 19, 2025--(BUSINESS WIRE)--Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom immunotherapy was not an option. These late-breaking results will be presented today during a proffered paper session (LBA21) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.","length":718,"tagName":"p"},{"type":"text","content":"DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).","length":231,"tagName":"p"},{"type":"text","content":"DATROWAY demonstrated a 5.0 month improvement in median OS compared to chemotherapy (hazard ratio [HR]=0.79; 95% confidence interval [CI]: 0.64-0.98; p=0.0291). Median OS was 23.7 months for patients treated with DATROWAY versus 18.7 months for ...